References
1-) Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19:141-154. doi: 10.1038/s41579-020-00459-7.
2-) https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
3-) Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802-810. doi: 10.1001/jamacardio.2020.0950
4-) Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34:2636-48, 2648a-2648d. doi: 10.1093/eurheartj/eht210.
5-) Modin D, Claggett B, Sindet-Pedersen C, Lassen MCH, Skaarup KG, Jensen JUS, et al. Acute COVID-19 and the Incidence of Ischemic Stroke and Acute Myocardial Infarction. Circulation. 2020;142:2080-2082. doi: 10.1161/CIRCULATIONAHA.120.050809.
6-) Bangalore S, Sharma A, Slotwiner A, Yatskar L, Harari R, Shah B, et al. ST-Segment Elevation in Patients with Covid-19 - A Case Series. N Engl J Med. 2020;382:2478-2480. doi: 10.1056/NEJMc2009020.
7-) Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. JAMA. 2020;324:799-801. doi: 10.1001/jama.2020.13372.
8-) Sandoval Y, Januzzi JL Jr, Jaffe AS. Cardiac Troponin for Assessment of Myocardial Injury in COVID-19: JACC Review Topic of the Week. J Am Coll Cardiol. 2020;76:1244-1258. doi: 10.1016/j.jacc.2020.06.068.
9-) Fox SE, Lameira FS, Rinker EB, Vander Heide RS. Cardiac Endotheliitis and Multisystem Inflammatory Syndrome After COVID-19. Ann Intern Med. 2020;173:1025-1027. doi: 10.7326/L20-0882.
10-) Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395:1417-1418. doi: 10.1016/S0140-6736(20)30937-5.
11-) Barbato E, Aarnoudse W, Aengevaeren WR, Werner G, Klauss V, Bojara W, et al. Validation of coronary flow reserve measurements by thermodilution in clinical practice. Eur Heart J. 2004;25:219-23. doi: 10.1016/j.ehj.2003.11.009.
12-) Lanza GA, Buffon A, Sestito A, Natale L, Sgueglia GA, Galiuto L, et al. Relation between stress-induced myocardial perfusion defects on cardiovascular magnetic resonance and coronary microvascular dysfunction in patients with cardiac syndrome X. J Am Coll Cardiol. 2008;51:466-72. doi: 10.1016/j.jacc.2007.08.060.
13-) Murthy VL, Naya M, Taqueti VR, Foster CR, Gaber M, Hainer J, et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes. Circulation. 2014;129:2518-27. doi: 10.1161/CIRCULATIONAHA.113.008507.
14-) Galiuto L, Sestito A, Barchetta S, Sgueglia GA, Infusino F, La Rosa C, et al. Noninvasive evaluation of flow reserve in the left anterior descending coronary artery in patients with cardiac syndrome X. Am J Cardiol. 2007;99:1378-83. doi: 10.1016/j.amjcard.2006.12.070.
15-) Caliskan M, Turan Y, Caliskan Z, et al. Previous gestational diabetes history is associated with impaired coronary flow reserve. Ann Med. 2015;47:615–623. doi:10.3109/07853890.2015.1099719
16-) Ciftci FC, Caliskan M, Ciftci O, et al. Impaired coronary microvascular function and increased intima-media thickness in preeclampsia. J Am Soc Hypertens. 2014;8:820–826. doi:10.1016/j.jash.2014.08.012
17-) Lowenstein CJ, Solomon SD. Severe COVID-19 Is a Microvascular Disease. Circulation. 2020;142:1609-1611. doi: 10.1161/CIRCULATIONAHA.120.050354.
18-) Landecho MF, Yuste JR, Gándara E, Sunsundegui P, Quiroga J, Alcaide AB, et al. COVID-19 retinal microangiopathy as an in vivo biomarker of systemic vascular disease? J Intern Med. 2021;289:116-120. doi: 10.1111/joim.13156.
19-) Carsetti A, Damiani E, Casarotta E, Scorcella C, Domizi R, Montomoli J, et al. Sublingual microcirculation in patients with SARS-CoV-2 undergoing veno-venous extracorporeal membrane oxygenation. Microvasc Res. 2020;132:104064. doi: 10.1016/j.mvr.2020.104064.
20-) Yin J, Wang S, Liu Y, Chen J, Li D, Xu T. Coronary microvascular dysfunction pathophysiology in COVID-19. Microcirculation. 2021:e12718. doi: 10.1111/micc.12718.
21-) Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271-280.e8. doi: 10.1016/j.cell.2020.02.052.
22-) Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203:631-7. doi: 10.1002/path.1570.
23-) Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417-1418. doi: 10.1016/S0140-6736(20)30937-5.
24-) Bearse M, Hung YP, Krauson AJ, Bonanno L, Boyraz B, Harris CK, et al. Factors associated with myocardial SARS-CoV-2 infection, myocarditis, and cardiac inflammation in patients with COVID-19. Mod Pathol. 2021;34:1345-1357. doi: 10.1038/s41379-021-00790-1.
25-) Bösmüller H, Traxler S, Bitzer M, Häberle H, Raiser W, Nann D, et al. The evolution of pulmonary pathology in fatal COVID-19 disease: an autopsy study with clinical correlation. Virchows Arch. 2020;477:349-357. doi: 10.1007/s00428-020-02881-x.
26-) Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res. 2020;191:148-150. doi: 10.1016/j.thromres.2020.04.041.
27-) O’Sullivan JM, Gonagle DM, Ward SE, Preston RJS, O’Donnell JS. Endothelial cells orchestrate COVID-19 coagulopathy. Lancet Haematol. 2020;7:e553-e555. doi: 10.1016/S2352-3026(20)30215-5.
28-) Karakike E, Giamarellos-Bourboulis EJ. Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis. Front Immunol. 2019;10:55. doi: 10.3389/fimmu.2019.00055.
29-) Abou-Arab O, Beyls C, Khalipha A, Guilbart M, Huette P, Malaquin S, et al. Microvascular flow alterations in critically ill COVID-19 patients: A prospective study. PLoS One. 2021;16:e0246636. doi: 10.1371/journal.pone.0246636.
30-) Tehrani S, Gille-Johnson P. Microvascular Dysfunction in Patients with Critical COVID-19, A Pilot Study. Shock. 2021 May 4. doi: 10.1097/SHK.0000000000001803.
31-) Sabioni L, De Lorenzo A, Lamas C, Muccillo F, Castro-Faria-Neto HC, Estato V, et al. Systemic microvascular endothelial dysfunction and disease severity in COVID-19 patients: Evaluation by laser Doppler perfusion monitoring and cytokine/chemokine analysis. Microvasc Res. 2021;134:104119. doi: 10.1016/j.mvr.2020.104119.
32-) Hoffman JI. Problems of coronary flow reserve. Ann Biomed Eng. 2000 Aug;28(8):884-96. doi: 10.1114/1.1308503. PMID: 11144672.
33-) Escher F, Pietsch H, Aleshcheva G, Bock T, Baumeier C, Elsaesser A, et al. Detection of viral SARS-CoV-2 genomes and histopathological changes in endomyocardial biopsies. ESC Heart Fail. 2020;7:2440-2447. doi: 10.1002/ehf2.12805.
34-) Park JH, Moon JY, Sohn KM, Kim YS. Two Fatal Cases of Stress-induced Cardiomyopathy in COVID-19 Patients. J Cardiovasc Imaging. 2020;28:300-303. doi: 10.4250/jcvi.2020.0125.